Divya K Chandra1, Alexander R Bazazi2, Muzammil A Nahaboo Solim3, Adeeba Kamarulzaman1,4, Frederick L Altice1,4,5, Gabriel J Culbert6,7. 1. a Department of Medicine , Section of Infectious Diseases, AIDS Program , Yale School of Medicine , New Haven , CT , USA. 2. b Department of Psychiatry , University of California, San Francisco School of Medicine , San Francisco , CA , USA. 3. c New Castle University Medicine , Johor , Malaysia. 4. d Centre of Excellence for Research in AIDS (CERiA) , University of Malaya , Kuala Lumpur , Malaysia. 5. e Department of Epidemiology of Microbial Diseases , Yale University School of Public Health , New Haven , CT , USA. 6. f Health Systems Science , Chicago College of Nursing, University of Illinois , Chicago , IL , USA. 7. g Center for HIV/AIDS Nursing Research , Faculty of Nursing, University of Indonesia , Depok , Indonesia.
Abstract
Background: Study retention is a major challenge in HIV clinical trials conducted with persons recruited from correctional facilities. Objective: To examine study retention in a trial of within-prison methadone initiation and a behavioral intervention among incarcerated men with HIV and opioid dependence in Malaysia. Methods: In this 2x2 factorial trial, 296 incarcerated men with HIV and opioid dependence were allocated to (1) an HIV risk reduction intervention, the Holistic Health Recovery Program for Malaysia (HHRP-M), (2) pre-release methadone initiation, (3) both interventions, or (4) standard care (NCT02396979). Here we estimate effects of these interventions on linkage to the study after prison release and completion of post-release study visits. Results: Most participants (68.9%) completed at least one post-release study visit but few (18.6%) completed all 12. HHRP-M was associated with a 13.5% (95% confidence interval (CI): 3.8%, 23.2%) increased probability of completing at least one post-release study visit. Although not associated with initial linkage, methadone treatment was associated with an 11% (95% CI: 2.0%, 20.6%) increased probability of completing all twelve post-release study visits. Being subject to forced relocation outside Kuala Lumpur after prison release decreased retention by 43.3% (95% CI: -51.9%, -34.8%). Conclusion: Retaining study participants in HIV clinical trials following prison release is challenging and potentially related to the broader challenges that participants experience during community reentry. Researchers conducting clinical trials with this population may want to consider methadone and HHRP as means to improve post-release retention, even in clinical trials where these interventions are not being directly evaluated.
RCT Entities:
Background: Study retention is a major challenge in HIV clinical trials conducted with persons recruited from correctional facilities. Objective: To examine study retention in a trial of within-prison methadone initiation and a behavioral intervention among incarcerated men with HIV and opioid dependence in Malaysia. Methods: In this 2x2 factorial trial, 296 incarcerated men with HIV and opioid dependence were allocated to (1) an HIV risk reduction intervention, the Holistic Health Recovery Program for Malaysia (HHRP-M), (2) pre-release methadone initiation, (3) both interventions, or (4) standard care (NCT02396979). Here we estimate effects of these interventions on linkage to the study after prison release and completion of post-release study visits. Results: Most participants (68.9%) completed at least one post-release study visit but few (18.6%) completed all 12. HHRP-M was associated with a 13.5% (95% confidence interval (CI): 3.8%, 23.2%) increased probability of completing at least one post-release study visit. Although not associated with initial linkage, methadone treatment was associated with an 11% (95% CI: 2.0%, 20.6%) increased probability of completing all twelve post-release study visits. Being subject to forced relocation outside Kuala Lumpur after prison release decreased retention by 43.3% (95% CI: -51.9%, -34.8%). Conclusion: Retaining study participants in HIV clinical trials following prison release is challenging and potentially related to the broader challenges that participants experience during community reentry. Researchers conducting clinical trials with this population may want to consider methadone and HHRP as means to improve post-release retention, even in clinical trials where these interventions are not being directly evaluated.
Entities:
Keywords:
Clinical trials; HIV; criminal justice; prisoners; study retention; substance use
Authors: Martin Y Iguchi; Jennifer A London; Nell Griffith Forge; Laura Hickman; Terry Fain; Kara Riehman Journal: Public Health Rep Date: 2002 Impact factor: 2.792
Authors: Mary Castle White; Jacqueline P Tulsky; Joe Goldenson; Carmen J Portillo; Masae Kawamura; Enrique Menendez Journal: Arch Intern Med Date: 2002-05-13
Authors: Karen A Robinson; Cheryl R Dennison; Dawn M Wayman; Peter J Pronovost; Dale M Needham Journal: J Clin Epidemiol Date: 2007-05-10 Impact factor: 6.437
Authors: Roman Ivasiy; Lynn M Madden; Scott O Farnum; Natalia Shumskaya; Samy J Galvez de Leon; Daniel J Bromberg; Ainura Kurmanalieva; Aibek Duishenaliev; Ruslan Tokubaev; Frederick L Altice Journal: Drug Alcohol Depend Rep Date: 2022-07-19